The effect of curcumin supplementation on Nonalcoholic Fatty Liver Disease

The effect of curcumin supplementation on lipid profile, liver enzymes, inflammatory factors and hepatic steatosis in patients with Nonalcoholic Fatty Liver Disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100524004010N24

Enrollment

Registered

2018-05-14

Start date

2017-04-09

Completion date

Unknown

Last updated

2018-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease. Other specified inflammatory liver diseases

Interventions

Intervention 1: Intervention group: 1.5 gram curcumin per day for 3 months. Intervention 2: Control group: 1.5 gram maltodextrin per day for 3 months.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age >18 years old Controlled Attenuation Parameter (CAP score)>263 Having a history of alcohol consumption less than 10 mg per day in women and less than 20 mg per day in men Absence of other acute and chronic diseases and disorders of the liver (hepatitis B, C, etc.), biliary disease, known autoimmune diseases, cancer and inherited disorders affecting liver condition (storage disease of iron, and copper. ..) Absence of Hypertension, cardio - vascular diseases, lung disease and kidney disease, cirrhosis and celiac disease Absence of pregnancy or lactation Athletes or hospitalization Not consume medications such as metformin, vitamin E and Ursodeoxycholic Acid (UDCA) Not consume hepatotoxic drugs such as phenytoin, tamoxifen and lithium and corticosteroids and methotrexate Not consume medications of antibiotics over a week during the study period or before entering it No history of weight loss surgery in the past year the 3-month weight loss program No history of hypothyroidism, Cushing's syndrome and diabetes Lack of gall bladder disease

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Type of supplement. Timepoint: Begining and end of the study. Method of measurement: Data collection forms.;LDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;HDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;TG. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;Total Cholestrol. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;AST. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;ALT. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;TNF-a. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Hs-CRP. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Cytokeratin-18. Timepoint: Begining and end of the study. Method of measurement: ELISA.;IL-6. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Hepatic Steatosis. Timepoint: Begining and end of the study. Method of measurement: Ultrasound.	—

Measure

Time frame

Type of supplement. Timepoint: Begining and end of the study. Method of measurement: Data collection forms.;LDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;HDL-C. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;TG. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;Total Cholestrol. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;AST. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;ALT. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;TNF-a. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Hs-CRP. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Cytokeratin-18. Timepoint: Begining and end of the study. Method of measurement: ELISA.;IL-6. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Hepatic Steatosis. Timepoint: Begining and end of the study. Method of measurement: Ultrasound.

—

Secondary

Measure	Time frame
FBS. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;Serum Insulin. Timepoint: Begining and end of the study. Method of measurement: Radioimmunoassay.;HOMA-IR. Timepoint: Begining and end of the study. Method of measurement: Calculation.;Ferritin. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Uric Acid. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Age. Timepoint: Begining of the study. Method of measurement: Question.;Sex. Timepoint: begining of the study. Method of measurement: observation.;Smoking. Timepoint: Begining of the study. Method of measurement: Questionare.;Height. Timepoint: Begining of the study. Method of measurement: Meter.;Weight. Timepoint: Begining and end of the study. Method of measurement: Balance.;BMI. Timepoint: Begining and end of the study. Method of measurement: Calculation.;Total Calorie Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Carbohydrate Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Protein Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fat Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fiber Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total MUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total PUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total SFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.	—

Measure

Time frame

FBS. Timepoint: Begining and end of the study. Method of measurement: Enzymatic method using a kit.;Serum Insulin. Timepoint: Begining and end of the study. Method of measurement: Radioimmunoassay.;HOMA-IR. Timepoint: Begining and end of the study. Method of measurement: Calculation.;Ferritin. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Uric Acid. Timepoint: Begining and end of the study. Method of measurement: ELISA.;Age. Timepoint: Begining of the study. Method of measurement: Question.;Sex. Timepoint: begining of the study. Method of measurement: observation.;Smoking. Timepoint: Begining of the study. Method of measurement: Questionare.;Height. Timepoint: Begining of the study. Method of measurement: Meter.;Weight. Timepoint: Begining and end of the study. Method of measurement: Balance.;BMI. Timepoint: Begining and end of the study. Method of measurement: Calculation.;Total Calorie Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Carbohydrate Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Protein Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fat Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total Fiber Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total MUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total PUFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.;Total SFA Intake. Timepoint: Begining and end of the study. Method of measurement: Recall Questionare.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAzita Hekmatdoost

Nutrition Faculty Of Shahid Beheshti University Of Medical Science

A_hekmat2000@yahoo.com+98 21 2237 6480

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 2, 2026